Pituitary surgery in Cushing's disease: first line treatment and role of reoperation

Pituitary. 2022 Oct;25(5):713-717. doi: 10.1007/s11102-022-01254-8. Epub 2022 Jul 20.

Abstract

Cushing's disease is the most common cause of endogenous hypercortisolemia, and transsphenoidal surgery remains the first line therapy for removal of the ACTH-secreting adenoma. While post-operative remission rates are high in experienced hands, there remains a 2% risk of recurrence per year. Patients with the highest chance for cure are those with small, non-invasive tumors that are visible on pre-operative MRI and identified during surgery and are performed by high-volume pituitary neurosurgeons. Surgery for persistent or recurrent disease is frequently indicated and is most successful in the hands of experienced surgeons and in cases where tumor is visible on MRI.

Keywords: Cushing’s disease; Cushing’s recurrence; Cushing’s remission; Transsphenoidal.

Publication types

  • Review

MeSH terms

  • Adenoma* / surgery
  • Adrenocorticotropic Hormone
  • Humans
  • Pituitary ACTH Hypersecretion* / surgery
  • Pituitary Neoplasms* / surgery
  • Reoperation
  • Treatment Outcome

Substances

  • Adrenocorticotropic Hormone